JOURNAL OF EXPERIMENTAL MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2025-02-16 ms5000002977722150 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫
经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。
我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的
后面不了一些实验
1月接收，
2月14online

16 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2025-02-14 ms2000000331101278 来自上海

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：免疫
经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发

15 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2022-04-16 1481188cm09(暂无昵称)

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫
经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据

112 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2024-01-30 solar93 来自广东省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：免疫
经验分享：建议免疫方向的文章

70 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2022-08-09 slientwo

JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！

114 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2021-06-21 1784370827m

审稿速度:1.0
偏重的研究方向：免疫
经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32

190 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2022-03-08 雪花莹

投稿命中率:50.0
偏重的研究方向：免疫
经验分享：这是时间点，坐等修回意见
Under External Review 2022-02-22
Initial Manuscript Assessment Started
Initial QC Complete 2022-02-10
Initial QC Started 2022-02-09
Author Approved Converted Files 2022-02-09
Preliminary Manuscript Data Submitted 2022-02-09

143 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2021-12-28 rayms

ORCIDID是什么？怎么注册？

131 1 举报

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2016-12-11 无敌的细胞

审稿速度:2.0 | 投稿命中率:5.0
经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。

585 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2252256, encodeId=eb3022522564b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：看网友的分享该期刊的审稿周期平均为3-8周还是比较准的。 我是24年11月送审，总共邀请来2个审稿人，意见都是比较正面的 后面不了一些实验 1月接收， 2月14online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms5000002977722150, createdTime=Sun Feb 16 23:06:42 CST 2025, time=2025-02-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2251847, encodeId=2635225184e51, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：免疫 经验分享：2024.12.03投稿，2024.12.16修回（2个中肯，1个问题很多，需要补1个实验）。2025.01.28修回意见提交，马上转入外部评审，2025.02.14预接收。总体算很快，也适合毕业和急发, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=15, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26149628607, createdName=ms2000000331101278, createdTime=Fri Feb 14 07:55:46 CST 2025, time=2025-02-14, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：1月送审，2个审稿人，意见都是比较positive 花了3个月补实验，然后过了1月接收，最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：免疫 经验分享：建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊，我都想要！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0 偏重的研究方向：免疫 经验分享：审稿都是免疫学大牛，很友好、提问相当专业。文章大修了3个figure，附时间点： Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0 偏重的研究方向：免疫 经验分享：这是时间点，坐等修回意见 Under External Review 2022-02-22 Initial Manuscript Assessment Started Initial QC Complete 2022-02-10 Initial QC Started 2022-02-09 Author Approved Converted Files 2022-02-09 Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么？怎么注册？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=131, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0 经验分享：近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒，直接转投JEM。3月投稿，中间修回一次，11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=585, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一审一个月给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=3, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=)]

2020-10-09 疯狂的丫头0731

审稿速度:1.0 | 投稿命中率:25.0
经验分享：一审一个月给大家个参考

3 1 举报

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务